

26. A process comprising the steps of:

- (a) performing the assay according to claim 24;
- (b) identifying one or more agents that do affect PDE1B2 expression; and
- (c) preparing a quantity of those one or more identified agents.

27. A method of affecting in vivo PDE1B2 expression with an agent, wherein the agent is capable of affecting PDE1B2 expression in an in vitro assay method; wherein the in vitro assay method is the assay method defined in claim 24, said method comprising administering said agent to a subject.


Remarks:

It is believed that the above-indicated claim amendments place the present case in condition for allowance. Therefore, a Notice of Allowance is courteously solicited.

Respectfully submitted,

Date:

9/15/00



Gregory P. Raymer
Attorney for Applicants
Reg. No. 36,647

Pfizer Inc
Patent Department
Eastern Point Road
Groton, CT 06340
(860) 715-5746

Express Mail No. EL709318798US

005160-7049900